<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00506857</url>
  </required_header>
  <id_info>
    <org_study_id>DM99-251</org_study_id>
    <nct_id>NCT00506857</nct_id>
  </id_info>
  <brief_title>Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support</brief_title>
  <official_title>Phase I/II Trial of Fludarabine in Combination With Intravenous Busulfan and Allogeneic Progenitor Cell Support for Patients With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives:

        1. To determine the relative toxicities, engraftment potential, kinetics of engraftment,
           degree of chimerism and disease control achieved with the combination of fludarabine and
           busulfan at different dose levels and different dose schedules in patients undergoing
           allogeneic stem cell transplant (SCT).

        2. Determine pharmacokinetics, and toxicity of intravenous busulfan given at equal total
           dose levels given four times daily, or once daily.

        3. In vivo determination of fludarabine inhibitory effects on DNA repair.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment: Participants will have blood tests and bone marrow tests as well as tests to check
      lung, heart, kidney, and liver functions. Participants will receive busulfan by vein for 2 to
      4 days depending on their age and medical condition. All participants will receive
      fludarabine which will be given over 4 days. Participants undergoing unmatched or matched
      unrelated donors will receive ATG over 4 days to help with the engraftment of the donor
      progenitor cells. All drugs are given through the vein daily.

      The donor blood cells will be taken from the donor through a process known as apheresis. This
      will occur after the donor has received 2 days of granulocyte colony stimulating factor
      (G-CSF) to increase her/his white cell count. The G-CSF will also increase the number of very
      immature (stem cells) that are to be collected. Apheresis is similar to a platelet donation,
      but white cells and stem cells are collected instead. About 3 to 5 apheresis procedures will
      be needed to get enough cells for infusion. If apheresis is not used, donor bone marrow will
      be taken under general anesthesia.

      After the participants receives the donor stem cells, the stem cells divide and reconstitute
      bone marrow function, blood function, and immunity. The donor stem cells are given after the
      chemotherapy to shorten the period of low blood counts. They are also given at this time to
      achieve an antileukemic effect whereby the donor immune cells will recognize the
      participant's leukemia as &quot;foreign&quot; and prevent its recurrence. A small amount of donor cells
      will be kept for infusion on a future date (usually 3 and 6 months post transplant) to try to
      prevent the disease from coming back.

      During the 4 to 8 weeks following blood cell infusion, participants will need frequent blood
      tests to monitor their counts and blood chemistries. Participants will need frequent blood
      transfusion and may have to be admitted to the hospital to receive antibiotics if they
      develop fever. Bone marrow will be examined frequently beginning four weeks after treatment
      to check response. Participants that achieve normal bone marrow and blood counts will be
      evaluated to determine the most appropriate form of future therapy. Participants who fail to
      respond to treatment will be offered other therapies.

      This is an investigational study. All through all drugs are commercially available. Up to 140
      participants will take part in this study. All will be enrolled at UT MD Anderson Cancer
      Center.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>1 month</time_frame>
    <description>Continual reassessment method (four times a day) used to determine an MTD, with a target toxicity probability of 20%, where &quot;toxicity&quot; is defined as grade 3 or 4 conventional toxicity [National Cancer Institute Common Toxicity Criteria (NCI-CTC)]. Participant evaluation in a cohort with each modality is 30 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Graft Versus Host Disease (GVHD)</measure>
    <time_frame>5 years</time_frame>
    <description>Tacrolimus and Methotrexate used for acute graft versus host disease (aGVHD) prophylaxis, clinical grading AGVHD criteria (Days 1-100): Grade 1: + to ++ skin rash; no gut involvement; no decrease in clinical performance status; Grade 2: + to +++ skin rash; + gut involvement and/or + liver involvement; mild decrease in performance status; Grade 3: ++ to +++ skin rash; ++ to +++ gut involvement and/or ++ to ++++ liver involvement; marked decrease in performance status; Grade 4: Similar to Grade 3 with ++ to ++++ organ involvement and extreme decrease in performance status.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>Busulfan + Fludarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Busulfan starting 0.8 mg/kg by vein (IV) every 6 hours for 12 doses; Fludarabine 30 mg/m^2 IV daily for 4 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Starting Dose 0.8 mg/kg by vein every 6 hours x 12 doses.</description>
    <arm_group_label>Busulfan + Fludarabine</arm_group_label>
    <other_name>Busulfex</other_name>
    <other_name>Myleran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>30 mg/m^2 by vein daily x 4 days.</description>
    <arm_group_label>Busulfan + Fludarabine</arm_group_label>
    <other_name>Fludarabine phosphate</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Less than physiologic 75 years of age.

          2. Interferon resistant late chronic phase CML not eligible for a protocol of higher
             priority.

          3. Accelerated/Blastic Phase CML.

          4. Acute leukemia or Intermediate to High Risk MDS according to the IPPS.

          5. Any Lymphoma or Myeloma beyond CR1 ineligible for a protocol of higher priority.

          6. Patients must have an HLA compatible donor willing to donate either peripheral blood
             or bone marrow progenitor cells.

          7. Both patients and donor must sign written informed consents.

        Exclusion Criteria:

          1. Uncontrolled infection

          2. Bilirubin &gt;3.0

          3. Creatinine &gt;2.5

          4. Performance Status &gt;Zubrod 2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard E. Champlin, MD, BS</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT MD Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center website</description>
  </link>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2007</study_first_submitted>
  <study_first_submitted_qc>July 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2007</study_first_posted>
  <results_first_submitted>January 24, 2012</results_first_submitted>
  <results_first_submitted_qc>January 24, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 28, 2012</results_first_posted>
  <last_update_submitted>January 24, 2012</last_update_submitted>
  <last_update_submitted_qc>January 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hematologic Malignancies</keyword>
  <keyword>Blood And Marrow Transplantation</keyword>
  <keyword>Leukemia</keyword>
  <keyword>MDS</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Myeloma</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>Fludara</keyword>
  <keyword>Fludarabine Phosphate</keyword>
  <keyword>Busulfan</keyword>
  <keyword>Busulfex</keyword>
  <keyword>Myleran</keyword>
  <keyword>Progenitor Cell Transplantation</keyword>
  <keyword>Granulocyte colony stimulating factor</keyword>
  <keyword>G-CSF</keyword>
  <keyword>Apheresis</keyword>
  <keyword>Blood cell infusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: November 2003 to August 2011. All recruitment was done at UT MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>Of the 82 participants enrolled, two (2) participants were excluded from the trial before starting treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Busulfan + Fludarabine</title>
          <description>Busulfan starting 0.8 mg/kg by vein (IV) every 6 hours for 12 doses; Fludarabine 30 mg/m^2 IV daily for 4 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Busulfan + Fludarabine</title>
          <description>Busulfan starting 0.8 mg/kg by vein (IV) every 6 hours for 12 doses; Fludarabine 30 mg/m^2 IV daily for 4 days.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" lower_limit="10" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD)</title>
        <description>Continual reassessment method (four times a day) used to determine an MTD, with a target toxicity probability of 20%, where &quot;toxicity&quot; is defined as grade 3 or 4 conventional toxicity [National Cancer Institute Common Toxicity Criteria (NCI-CTC)]. Participant evaluation in a cohort with each modality is 30 days.</description>
        <time_frame>1 month</time_frame>
        <population>Analysis was per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Busulfan + Fludarabine</title>
            <description>Busulfan starting 0.8 mg/kg by vein (IV) every 6 hours for 12 doses; Fludarabine 30 mg/m^2 IV daily for 4 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (MTD)</title>
          <description>Continual reassessment method (four times a day) used to determine an MTD, with a target toxicity probability of 20%, where &quot;toxicity&quot; is defined as grade 3 or 4 conventional toxicity [National Cancer Institute Common Toxicity Criteria (NCI-CTC)]. Participant evaluation in a cohort with each modality is 30 days.</description>
          <population>Analysis was per protocol.</population>
          <units>mg/kg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Graft Versus Host Disease (GVHD)</title>
        <description>Tacrolimus and Methotrexate used for acute graft versus host disease (aGVHD) prophylaxis, clinical grading AGVHD criteria (Days 1-100): Grade 1: + to ++ skin rash; no gut involvement; no decrease in clinical performance status; Grade 2: + to +++ skin rash; + gut involvement and/or + liver involvement; mild decrease in performance status; Grade 3: ++ to +++ skin rash; ++ to +++ gut involvement and/or ++ to ++++ liver involvement; marked decrease in performance status; Grade 4: Similar to Grade 3 with ++ to ++++ organ involvement and extreme decrease in performance status.</description>
        <time_frame>5 years</time_frame>
        <population>Analysis was per protocol for 73 patients out of 80 patients due to 3 early deaths and 4 non engraftments.</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus + Methotrexate</title>
            <description>Busulfan starting 0.8 mg/kg by vein (IV) every 6 hours for 12 doses; Fludarabine 30 mg/m^2 IV daily for 4 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Graft Versus Host Disease (GVHD)</title>
          <description>Tacrolimus and Methotrexate used for acute graft versus host disease (aGVHD) prophylaxis, clinical grading AGVHD criteria (Days 1-100): Grade 1: + to ++ skin rash; no gut involvement; no decrease in clinical performance status; Grade 2: + to +++ skin rash; + gut involvement and/or + liver involvement; mild decrease in performance status; Grade 3: ++ to +++ skin rash; ++ to +++ gut involvement and/or ++ to ++++ liver involvement; marked decrease in performance status; Grade 4: Similar to Grade 3 with ++ to ++++ organ involvement and extreme decrease in performance status.</description>
          <population>Analysis was per protocol for 73 patients out of 80 patients due to 3 early deaths and 4 non engraftments.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>March 2000 to December 2004 (4 years, 8 months)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Busulfan + Fludarabine</title>
          <description>Busulfan starting 0.8 mg/kg by vein (IV) every 6 hours for 12 doses; Fludarabine 30 mg/m^2 IV daily for 4 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Graft failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Chronic Graft versus Host Disease</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Acute Graft versus Host Disease</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated alanine aminotransferase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diffuse alveolar haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Occular</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Stomatitis/Esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated alkaline phosphate</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Elevated alanine aminotransferase</sub_title>
                <description>Diarrhea</description>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered mental status</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Hemorrhagic cystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Richard E. Champlin/Professor</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <email>ytdinh@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

